Dolutegravir Resistance in Malawi’s National HIV Treatment Program

Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020–September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 (30%...

Descripción completa

Detalles Bibliográficos
Autores principales: van Oosterhout, Joep J, Chipungu, Chifundo, Nkhoma, Lyse, Kanise, Hope, Hosseinipour, Mina C, Sagno, Jean Babtiste, Simon, Katherine, Cox, Carrie, Hoffman, Risa, Steegen, Kim, Matola, Bilaal W, Phiri, Sam, Jahn, Andreas, Nyirenda, Rose, Heller, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045949/
https://www.ncbi.nlm.nih.gov/pubmed/35493118
http://dx.doi.org/10.1093/ofid/ofac148
_version_ 1784695419105705984
author van Oosterhout, Joep J
Chipungu, Chifundo
Nkhoma, Lyse
Kanise, Hope
Hosseinipour, Mina C
Sagno, Jean Babtiste
Simon, Katherine
Cox, Carrie
Hoffman, Risa
Steegen, Kim
Matola, Bilaal W
Phiri, Sam
Jahn, Andreas
Nyirenda, Rose
Heller, Tom
author_facet van Oosterhout, Joep J
Chipungu, Chifundo
Nkhoma, Lyse
Kanise, Hope
Hosseinipour, Mina C
Sagno, Jean Babtiste
Simon, Katherine
Cox, Carrie
Hoffman, Risa
Steegen, Kim
Matola, Bilaal W
Phiri, Sam
Jahn, Andreas
Nyirenda, Rose
Heller, Tom
author_sort van Oosterhout, Joep J
collection PubMed
description Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020–September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 (30%) had dolutegravir HIVDR. Malawi urgently requires adequate HIVDR testing capacity.
format Online
Article
Text
id pubmed-9045949
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-90459492022-04-28 Dolutegravir Resistance in Malawi’s National HIV Treatment Program van Oosterhout, Joep J Chipungu, Chifundo Nkhoma, Lyse Kanise, Hope Hosseinipour, Mina C Sagno, Jean Babtiste Simon, Katherine Cox, Carrie Hoffman, Risa Steegen, Kim Matola, Bilaal W Phiri, Sam Jahn, Andreas Nyirenda, Rose Heller, Tom Open Forum Infect Dis Brief Report Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020–September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 (30%) had dolutegravir HIVDR. Malawi urgently requires adequate HIVDR testing capacity. Oxford University Press 2022-04-05 /pmc/articles/PMC9045949/ /pubmed/35493118 http://dx.doi.org/10.1093/ofid/ofac148 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
van Oosterhout, Joep J
Chipungu, Chifundo
Nkhoma, Lyse
Kanise, Hope
Hosseinipour, Mina C
Sagno, Jean Babtiste
Simon, Katherine
Cox, Carrie
Hoffman, Risa
Steegen, Kim
Matola, Bilaal W
Phiri, Sam
Jahn, Andreas
Nyirenda, Rose
Heller, Tom
Dolutegravir Resistance in Malawi’s National HIV Treatment Program
title Dolutegravir Resistance in Malawi’s National HIV Treatment Program
title_full Dolutegravir Resistance in Malawi’s National HIV Treatment Program
title_fullStr Dolutegravir Resistance in Malawi’s National HIV Treatment Program
title_full_unstemmed Dolutegravir Resistance in Malawi’s National HIV Treatment Program
title_short Dolutegravir Resistance in Malawi’s National HIV Treatment Program
title_sort dolutegravir resistance in malawi’s national hiv treatment program
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045949/
https://www.ncbi.nlm.nih.gov/pubmed/35493118
http://dx.doi.org/10.1093/ofid/ofac148
work_keys_str_mv AT vanoosterhoutjoepj dolutegravirresistanceinmalawisnationalhivtreatmentprogram
AT chipunguchifundo dolutegravirresistanceinmalawisnationalhivtreatmentprogram
AT nkhomalyse dolutegravirresistanceinmalawisnationalhivtreatmentprogram
AT kanisehope dolutegravirresistanceinmalawisnationalhivtreatmentprogram
AT hosseinipourminac dolutegravirresistanceinmalawisnationalhivtreatmentprogram
AT sagnojeanbabtiste dolutegravirresistanceinmalawisnationalhivtreatmentprogram
AT simonkatherine dolutegravirresistanceinmalawisnationalhivtreatmentprogram
AT coxcarrie dolutegravirresistanceinmalawisnationalhivtreatmentprogram
AT hoffmanrisa dolutegravirresistanceinmalawisnationalhivtreatmentprogram
AT steegenkim dolutegravirresistanceinmalawisnationalhivtreatmentprogram
AT matolabilaalw dolutegravirresistanceinmalawisnationalhivtreatmentprogram
AT phirisam dolutegravirresistanceinmalawisnationalhivtreatmentprogram
AT jahnandreas dolutegravirresistanceinmalawisnationalhivtreatmentprogram
AT nyirendarose dolutegravirresistanceinmalawisnationalhivtreatmentprogram
AT hellertom dolutegravirresistanceinmalawisnationalhivtreatmentprogram

Ejemplares similares